South Korean biotechnology firm Boostimmune has announced a significant intellectual property milestone with the grant of a new Japanese patent. This patent protects a novel technology that uses antibodies to inhibit a key protein involved in cancer's immune evasion. The development strengthens the foundation for the company's lead immuno-oncology candidate, BIO101, and its potential to treat cancer by modulating the tumor microenvironment.
A Novel Approach to Immuno-Oncology
The company's research targets the Translationally Controlled Tumor Protein (TCTP), which is released from dying tumor cells. This extracellular TCTP recruits immunosuppressive cells known as Myeloid-Derived Suppressor Cells (MDSCs) into the tumor. These MDSCs then create a barrier that prevents the body's own immune system from effectively attacking the cancer cells.
Boostimmune's therapeutic strategy involves an antibody designed to block this extracellular TCTP, preventing it from signaling MDSCs. By inhibiting the accumulation of these suppressor cells, the treatment aims to restore the natural anti-tumor immune response. This approach represents a promising new way to overcome one of cancer's primary defense mechanisms.
Broad Intellectual Property Protection
The newly granted patent is notable for its broad scope, defining the protected antibody by its function rather than a specific amino acid sequence. It covers any anti-TCTP antibody that inhibits the protein's activity and suppresses MDSC accumulation in the tumor microenvironment. This functional definition provides a robust and comprehensive intellectual property shield for the underlying therapeutic mechanism.
This strategic patenting approach extends protection to the inhibition of polymorphonuclear MDSCs (PMN-MDSCs) and any related cancer therapeutics containing the inhibitor. By securing such wide-ranging claims, Boostimmune has fortified its competitive position in the Japanese market. The patent is a critical asset for the future development, licensing, and commercialization of TCTP-targeting therapies.
Scientific Origins and Development Path
The BIO101 program is built upon foundational research from the laboratory of Professor Tadatsugu Taniguchi, a globally recognized immunologist at the University of Tokyo. Professor Taniguchi, who is also a co-founder of Boostimmune, led the team that first uncovered this TCTP-MDSC pathway. The program was subsequently in-licensed by the company to translate the discovery into a clinical candidate.
The team's groundbreaking findings were published in the prestigious journal Nature Immunology in 2021, detailing how extracellular TCTP promotes MDSC accumulation. Building on this research, Boostimmune has identified and optimized antibody candidates like BIO101. The company has focused on enhancing antibody binding properties and confirming the inhibition of MDSC accumulation to activate anti-tumor immunity.
Strategic Implications and Future Outlook
Gwanghee Lee, CEO of Boostimmune, highlighted the patent's significance, noting its focus on the functional mechanism rather than a single antibody sequence. This provides a powerful advantage for the BIO101 program and any similar therapeutic approaches. The patent is considered a crucial intellectual property right for advancing TCTP-targeting antibody therapeutics in Japan.
With this key patent secured, the company plans to accelerate the development of BIO101. Boostimmune is also actively pursuing strategic collaborations with global pharmaceutical and biotechnology partners. These partnerships will be essential for advancing its pipeline, which includes BIO101 and novel antibody-drug conjugate programs.
The grant of this Japanese patent marks a pivotal achievement for Boostimmune, validating its innovative scientific approach to immuno-oncology. It provides a strong commercial and developmental foundation for BIO101 and other TCTP-targeting antibodies. This milestone positions the company to make significant strides in developing a new class of therapeutics aimed at overcoming immune suppression within the tumor microenvironment.